文献速递乳腺癌

少即是多:AMAROS随机对照试验10年更新结果如何影响淋巴结阳性乳腺癌的腋窝管理

When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
PubMed 文献 · J Clin Oncol · 2023-02-27

本文以一位新辅助内分泌治疗有效的早期浸润性导管癌患者为例,其临床淋巴结阴性但病理淋巴结阳性,在关注疗效与减少淋巴水肿风险的背景下,结合AMAROS试验10年随访数据,讨论腋窝局部控制措施对临床实践的影响,并支持医患共同决策。

要点

  • 早期乳腺癌治疗中,全身治疗改善背景下手术降阶梯可带来更好的患者结局。
  • AMAROS试验10年随访数据增进了对腋窝局部控制措施影响的认识。
  • AMAROS研究结果所展示的概念可应用于临床实践,帮助做出合理治疗选择并支持共同决策。

核心结论

  • AMAROS试验10年随访数据增进了对腋窝局部控制措施影响的认识。
  • AMAROS研究结果所展示的概念可应用于临床实践,帮助做出合理治疗选择并支持医患共同决策。

研究设计与样本

  • 本文为肿瘤学大查房系列文章,先呈现病例,再描述诊断与管理挑战、复习相关文献并总结作者建议的管理方法。

主要发现

  • 病例为一位早期浸润性导管癌患者,对新辅助内分泌治疗有反应,随后接受部分乳房切除加腋窝前哨淋巴结活检。
  • 该患者临床淋巴结阴性,但病理淋巴结阳性。

临床怎么用

  • 作者建议将AMAROS研究结果所展示的概念应用于临床实践,以帮助做出合理治疗选择并支持医患共同决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.It is important to reflect on how far we as a medical community have come when treating breast cancer. Ongoing research, clinical trials, and better understanding of biology have transformed our understanding and treatment of breast cancer. There is still much to learn. Although progress was slow for decades, treatments have evolved more quickly in the recent past. The Halsted radical mastectomy, first popularized in 1894, was performed for almost a century, and although it decreased local recurrence, it did not improve survival. This well-intentioned surgery disfigured women and was abandoned as better systemic therapies were introduced and less aggressive surgical procedures were found to be equivalent in clinical trials. The evolution of trials in the modern era has taught us an important lesson. De-escalation of surgical interventions in the setting of improved systemic therapy can lead to better patient outcomes. We present a case of a clinician with an early-stage invasive ductal carcinoma responsive to neoadjuvant endocrine therapy and who subsequently underwent a partial mastectomy with axillary sentinal lymph node biopsy. Although clinically node-negative, she was pathologically node-positive, and concerned about both optimizing her outcomes and minimizing the risk of lymphedema. The release of 10-year follow-up data from the AMAROS trial furthers our knowledge and understanding of the impact of local control measures of the axilla. The concepts illustrated by the findings of AMAROS may be applied in clinical practice and ultimately help us make rational treatment choices and support shared decision making for patients like ours.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Esserman LJ, Ali H, McKenzie T, et al. When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node. J Clin Oncol. 2023. PMID: 36848617. doi:10.1200/JCO.22.02070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。